A Real-World Comparison of Drug Trough Levels between Patients Experiencing a Secondary Nonimmune Loss of Response and Those Maintaining a Response to Infliximab on Long-Term Maintenance Therapy for Inflammatory Bowel Disease.

There was a nonsignificant trend toward longer mean duration of concomitant immunomodulator use in those without LOR at 2.39 years versus 1.08 years for those with LOR, p = 0.252.

also in 5,406 other papers

Using the currently accepted/minimum IFX level of 5 μg/mL as a cutoff for inclusion, our comparison of IFX levels for those with versus without LOR did not demonstrate any significant difference in trough levels and in fact showed a trend toward higher levels for those with LOR.

also in 53,322 other papers